Lurasidone - Sumitomo Dainippon Pharma

Drug Profile

Lurasidone - Sumitomo Dainippon Pharma

Alternative Names: DSP-1349M; Latuda; Lurasidone HCl; Lurasidone hydrochloride; Lurasidone injectable suspension; Lurasidone injection suspension; SM-13496; SMP-13496

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Bukwang Pharmaceutical; Daiichi Sankyo Company; DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Takeda
  • Class Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder; Psychiatric disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Jun 2018 Phase-I clinical trials in Schizophrenia in USA (Parenteral) (NCT03627195)
  • 20 Apr 2018 Launched for Bipolar depression (In adolescents, Monotherapy) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top